{"disease":{"id":"exudative-age-related-macular-degeneration","name":"Exudative age-related macular degeneration","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"faricimab","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vabysmo","generic_name":"FARICIMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":62,"revenue":"5500","mechanism":"Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A."},{"drug_id":"visudyne","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Visudyne","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"eylea","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"faricimab-svoa","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VABYSMO","generic_name":"FARICIMAB-SVOA","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"Angiopoietin-2, Vascular endothelial growth factor A","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"lucentis","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pegaptanib","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Macugen","generic_name":"pegaptanib","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"brolucizumab","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beovu","generic_name":"BROLUCIZUMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation."},{"drug_id":"eye001","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Macugen","generic_name":"EYE001","company_name":"Valeant Pharms Llc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"beovu","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beovu","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"macugen","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Macugen","company_name":"Greater Houston Retina Research","drug_phase":"discontinued","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"verteporfin","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Visudyne","generic_name":"VERTEPORFIN","company_name":"Bausch Lomb Ireland","drug_phase":"marketed","molecular_target":"","drug_class":"Photoenhancer [EPC]","quality_score":10,"revenue":null,"mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction."},{"drug_id":"ranibizumab-nuna","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"anecortave","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retaane","generic_name":"anecortave","company_name":"","drug_phase":"marketed","molecular_target":"Plasminogen activator inhibitor 1","drug_class":"anecortave","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04723160","title":"Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph","phase":"","overall_status":"COMPLETED","enrollment_count":748,"lead_sponsor_name":"Visionary Intelligence Ltd.","has_results":false},{"nct_id":"NCT07328776","title":"An Assistant Model for Anti-VEGF Therapy Decision","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT02348359","title":"X-82 to Treat Age-related Macular Degeneration","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":157,"lead_sponsor_name":"Tyrogenex","has_results":true},{"nct_id":"NCT02355028","title":"LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Alcon, a Novartis Company","has_results":true},{"nct_id":"NCT05832996","title":"Cool vs Room-temperature Artificial Tears","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"University of Iowa","has_results":true},{"nct_id":"NCT05447650","title":"Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"i-Lumen Scientific, Inc.","has_results":false},{"nct_id":"NCT04200248","title":"A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Ribomic USA Inc","has_results":true},{"nct_id":"NCT05539235","title":"Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT07235527","title":"Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Saglik Bilimleri Universitesi","has_results":false},{"nct_id":"NCT00447954","title":"A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Neurotech Pharmaceuticals","has_results":true},{"nct_id":"NCT04504123","title":"MMP-9 Inhibition for Recalcitrant Wet AMD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT04640272","title":"A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Ribomic USA Inc","has_results":true},{"nct_id":"NCT04138420","title":"Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab","phase":"","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT03071055","title":"Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Southeast Clinical Research Associates, LLC","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}